Authors: Benjamin M. Johnson, Bently P. Doonan, Faisal F. Radwan, and Azizul Haque
Published online on: Jan 1, 2010.
Conclusion of this report (Full Report)
Prostate cancer is a major cause of death among men in the western world. Current treatment and therapeutic options are beneficial to early stage patients but lack significant benefit to metastatic, late-stage patients. Prostate cancer preferentially metastasizes to bone, exploiting the normal cellular processes of bone formation and resorption to invade and colonize bone cells. Another point of emphasis in prostate cancer therapy is the targeting of androgens. Both 5-α-reductase and the AR play crucial roles in prostate cancer development. 5-α-reductase catalyzes testosterone to DHT, and then binds to the androgen receptor, promoting cell survival and proliferation. Based on these factors, research involving immunotherapy, chemoimmunotherapy, and even herbal therapeutics is of great importance and interest. While many immunotherapeutic and chemotherapeutic agents have been studied in clinical trials, finding an agent with significant toxicity to tumor cells and limited toxicity to bystander cells remains a challenge. G. lucidummushroom extracts are cytotoxic to tumor cells with some GA subtypes having anti-metastatic properties. While extensive work has been performed using GA subtypes in breast and lung cancers, the effects of GA subtypes on prostate cancer are less clear. Studies involving GA-DM are of particular interest because GA-DM treatment has shown cytotoxicity in prostate cancer cells regardless of their dependence on androgens. GA-DM has been shown to limit the conversion of testosterone to DHT and prevent DHT binding to the androgen receptor through competitive inhibition. GA-DM has also been implicated in the inhibition of osteoclastogenesis, a process exploited by certain prostate cancer cells to promote bone metastasis. While GA-DM remains promising, introduction of GA-DM-infused-nanoparticles with targeted delivery to malignant cells could be an alternative approach to combat advanced prostate cancer. Taken together, this review suggests the potential benefits of GA-DM in treating advanced metastatic prostate cancer.
LIST OF ABBREVIATIONS
- GA – ganoderic acid
- MMP – matrix metallonproteinase
- CRPC – castrate resistant prostate cancer
- BPH – benign prostatic hyperplasia
- RANK – receptor factor for nuclear factor κ B
- VEGF – vascular endothelial growth factor
- PSA – Prostate Specific Antigen
- DHT – dihydrotestosterone
- AR – androgen receptor
- IONP – ion oxide nanoparticle
Yesterday I just got to know that, 5 years ago, an uncle who diagnosed with prostrate cancer (terminal stage) cleared after 5 months taking high-dosage lingzhi and other health food supplement. He almost give up one month after taking the lingzhi because of the severe healing crisis which he almost unable to endure due to old age. But fortunately he didn’t give up and continue to take it and eventually 5 months later, his cancer was cleared. If you like to know more of this case and what else he do to get healed, you can contact me ya.
Extra Info from this book – Healing Without Medication: A Comprehensive Guide to the Complementary Techniques Anyone Can Use to Achieve Real Healing – by Robert S. Rister
- Difficulty starting or stopping stream of urine.
- Increased frequency of urination.
- Pain while urinating.
- Blood in urine (rare).
- Impotence (rare as a result of the disease itself)
- Usually no symptoms, condition discovered when a rectal exam is performed